Vimgreen Pharmaceuticals, a prominent company focused on modulating adenosine signaling pathways, has announced that China’s Center for Drug Evaluation (CDE) has cleared its Investigational New Drug (IND) application for VG081821 in non-alcoholic steatohepatitis (NASH), now more commonly termed metabolic dysfunction-associated steatohepatitis (MASH). This milestone marks the second clinical application for the company’s lead candidate, which is already being developed for Parkinson’s disease.
The approval represents the first worldwide authorization to study an A2A receptor antagonist in NASH. With this clearance, VG081821 can move directly into Phase II trials for NASH, accelerating its clinical development timeline as a potential novel therapy.
NASH is a chronic liver condition marked by fat buildup (steatosis), liver cell damage, inflammation, and progressive scarring (fibrosis). As obesity and metabolic disorders continue to rise globally, NASH has become a major contributor to cirrhosis and liver cancer. Despite its growing impact, treatment options remain scarce, with only two drugs—resmetirom and semaglutide—receiving accelerated approvals so far, highlighting a significant unmet medical need.
VG081821 works as an A2A receptor antagonist, targeting the three key drivers of NASH: fat accumulation, inflammation, and fibrosis. This broad mechanism of action is particularly advantageous given the disease’s complex biology, positioning the drug as a strong therapeutic contender.
Epidemiological research further supports this approach. Several large studies have linked moderate coffee consumption with a reduced risk of chronic liver disease. Caffeine, the primary active compound in coffee, provides liver-protective effects largely by inhibiting A2A receptors. VG081821, being more potent and selective than caffeine, is designed to enhance these benefits with greater precision.
What sets VG081821 apart from conventional A2A receptor blockers like istradefylline is its unique pharmacological behavior. While standard antagonists simply prevent receptor activation, VG081821 functions as an inverse agonist—reducing both stimulated and baseline receptor activity. This dual action may result in more comprehensive suppression of harmful signaling pathways and improved therapeutic outcomes.
The drug is also being developed for Parkinson’s disease, where it aims to address both symptoms and underlying disease processes. In Phase II studies involving patients with early to mid-stage Parkinson’s, VG081821 showed meaningful improvements in motor function and met key efficacy targets, indicating strong potential as a standalone treatment. The main side effect observed was a temporary rise in liver transaminases, likely due to metabolic changes in the liver rather than toxicity. Similar transient effects have been noted with other lipid-modulating therapies and are generally considered harmless adaptive responses.
Sanxing Sun, President and CEO of Vimgreen Pharmaceuticals, expressed enthusiasm about the progress, noting that VG081821’s mechanism differs significantly from existing THR-beta agonists and GLP-1–based treatments. By enhancing hepatic lipid processing while reducing inflammation and fibrosis, the therapy is well-positioned to address critical gaps in metabolic liver disease treatment and improve patient outcomes.
The company plans to begin a Phase IIa clinical trial for NASH in the latter half of the year.
The approval represents the first worldwide authorization to study an A2A receptor antagonist in NASH. With this clearance, VG081821 can move directly into Phase II trials for NASH, accelerating its clinical development timeline as a potential novel therapy.
NASH is a chronic liver condition marked by fat buildup (steatosis), liver cell damage, inflammation, and progressive scarring (fibrosis). As obesity and metabolic disorders continue to rise globally, NASH has become a major contributor to cirrhosis and liver cancer. Despite its growing impact, treatment options remain scarce, with only two drugs—resmetirom and semaglutide—receiving accelerated approvals so far, highlighting a significant unmet medical need.
VG081821 works as an A2A receptor antagonist, targeting the three key drivers of NASH: fat accumulation, inflammation, and fibrosis. This broad mechanism of action is particularly advantageous given the disease’s complex biology, positioning the drug as a strong therapeutic contender.
Epidemiological research further supports this approach. Several large studies have linked moderate coffee consumption with a reduced risk of chronic liver disease. Caffeine, the primary active compound in coffee, provides liver-protective effects largely by inhibiting A2A receptors. VG081821, being more potent and selective than caffeine, is designed to enhance these benefits with greater precision.
What sets VG081821 apart from conventional A2A receptor blockers like istradefylline is its unique pharmacological behavior. While standard antagonists simply prevent receptor activation, VG081821 functions as an inverse agonist—reducing both stimulated and baseline receptor activity. This dual action may result in more comprehensive suppression of harmful signaling pathways and improved therapeutic outcomes.
The drug is also being developed for Parkinson’s disease, where it aims to address both symptoms and underlying disease processes. In Phase II studies involving patients with early to mid-stage Parkinson’s, VG081821 showed meaningful improvements in motor function and met key efficacy targets, indicating strong potential as a standalone treatment. The main side effect observed was a temporary rise in liver transaminases, likely due to metabolic changes in the liver rather than toxicity. Similar transient effects have been noted with other lipid-modulating therapies and are generally considered harmless adaptive responses.
Sanxing Sun, President and CEO of Vimgreen Pharmaceuticals, expressed enthusiasm about the progress, noting that VG081821’s mechanism differs significantly from existing THR-beta agonists and GLP-1–based treatments. By enhancing hepatic lipid processing while reducing inflammation and fibrosis, the therapy is well-positioned to address critical gaps in metabolic liver disease treatment and improve patient outcomes.
The company plans to begin a Phase IIa clinical trial for NASH in the latter half of the year.